Da Hee Han, PharmD

Most Recent Articles by Da Hee Han, PharmD

Alunbrig Granted Accelerated Approval for Metastatic NSCLC

By Apr 28, 2017

Overall response rate for brigatinib in the 90mg arm was 48% (95% CI: 39%, 58%) and was 53% (95% CI: 43%, 62%) in the 180mg arm

CDC: Tackling the Yellow Fever Vaccine Supply Shortage in U.S.

By Apr 28, 2017

The diminishing supply of YF-VAX started in November 2015 as Sanofi Pasteur was shifting to a newer production facility set to open in 2018.

Rydapt Approved for Acute Myeloid Leukemia, Mastocytosis

By Apr 28, 2017

Rydapt works by inhibiting multiple receptor tyrosine kinases.

Powder Form of Ilaris Permanently Discontinued

By Apr 28, 2017

Ilaris for Injection will be replaced by Ilaris Injection (solution) for subcutaneous use.

Amneal Introduces New Strength of Thiotepa with Tepadina

By Apr 27, 2017

Tepadina, an alkylating agent, is indicated to reduce the risk of graft rejection when used with high-dose busulfan and cyclophosphamide as a preparative regimen for allogeneic hematopoietic progenitor (stem) cell transplantation (HSCT) for pediatric patients with class 3 beta-thalassemia.

More Articles by Da Hee Han, PharmD